TAIPEI, November 5, 2026 -- TaiMed Biologics (TPEX: 4147), a commercial-stage CD4-targeted biologics company advancing antibody-based therapies for long-acting HIV treatment, today announced that it will present 24-week clinical data from its Phase 2a maintenance study of the TMB-365/TMB-380 combination regimen, administered every eight weeks, in an oral presentation at HIV Drug Therapy Glasgow 2026 (HIV Glasgow 2026), taking place November 8–11, 2026, in Glasgow, Scotland. The company will also present an encore poster on its Phase 1 single-dose escalation study of TMB-365, which was presented orally at IDWeek 2026.

"The Phase 2a study evaluated whether TMB-365/TMB-380, given every eight weeks, could maintain viral suppression as a stand-alone regimen in people living with HIV-1 who switched from combination antiretroviral therapy," said Jimmy Chang, PhD, Chief Executive Officer of TaiMed Biologics. "HIV Glasgow brings together clinicians and researchers focused on HIV treatment, and we look forward to sharing these results and discussing the role an antibody-only, long-acting regimen could play in maintenance treatment."

The details of the presentations are as follows:

Oral Presentation on Phase 2a Maintenance Study of TMB-365/TMB-380
Title: A 24-week phase 2a maintenance study of TMB-365/TMB-380 q8w in people with suppressed HIV-1 infection (O31)
Presenting author: Martin Markowitz, MD, Columbia University Irving Medical Center
Session: Novel Strategies and Treatment
Date/Time: November 10, 2026 / 10:55 AM – 11:07 AM GMT
Location: Clyde, Scottish Event Campus (SEC)

Encore Poster Presentation on Phase 1 Single-Dose Escalation Study of TMB-365
Title: Single-dose escalation study of TMB-365 in people living with HIV: safety, pharmacokinetics and antiviral activity (P040)
Presenting author: Martin Markowitz, MD, Columbia University Irving Medical Center
Session: Treatment strategies: Novel therapeutic targets (phase I and II)
Date/Time: November 8–11, 2026
Location: Exhibition Hall 4, Scottish Event Campus (SEC)